Generate Biomedicines (GENB) was upgraded by Zacks Research to "hold".
Generate Biomedicines (GENB) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating and a $26.00 price target on the stock.
Generate Biomedicines (GENB) is now covered by Morgan Stanley. They set an "overweight" rating and a $20.00 price target on the stock.
Generate Biomedicines (GENB) is now covered by Piper Sandler. They set an "overweight" rating and a $24.00 price target on the stock.
Generate Biomedicines (GENB) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.